Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Galapagos Selects Pre-Clinical Candidate for Cystic Fibrosis

Published: Tuesday, December 17, 2013
Last Updated: Tuesday, December 17, 2013
Bookmark and Share
Start of Phase 1 expected before end 2014.

Galapagos NV has announced that it has nominated a pre-clinical candidate potentiator for clinical development in its cystic fibrosis (CF) program.

Galapagos has developed multiple, novel potentiators that, in pre-clinical research, show high potency and superior efficacy in comparison to Kalydeco® (ivacaftor),the only approved disease-modifying CF drug on the market.

Furthermore, the Galapagos compounds show good drug-like properties, which support further pre-clinical development. The clean safety profile of these compounds should allow the combination with antibiotics frequently prescribed for CF patients.

From these series, Galapagos selected GLPG1837 as pre-clinical candidate and expects to start the first clinical trial before end 2014. Galapagos recently filed a patent application covering GLPG1837, with the expected patent life until at least 2034.

"Galapagos had several excellent compounds to choose from among its novel CF potentiators. GLPG1837 forms the first part of our strategy to develop novel and best-in-class therapies for CF. The Galapagos-AbbVie team is now fully ramped up to progress our correctors, which are needed in combination with the potentiator to address the unmet need of most CF patients," said Dr Piet Wigerinck, Chief Scientific Officer of Galapagos.

Galapagos initiated its research in CF in 2005 as part of a collaboration with the Cystic Fibrosis Foundation. In September 2013 Galapagos signed an agreement with AbbVie in which they will work collaboratively to develop and commercialize oral drugs that address the main mutations in CF patients, including F508del and G551D.

Under the terms of the agreement, AbbVie made an upfront payment of $45 million to Galapagos. Upon successful completion of pre-determined success milestones, AbbVie and Galapagos will share responsibility and funding for Phase III clinical development.

Galapagos is eligible to receive up to $360 million in total additional payments for developmental and regulatory milestones, sales milestones upon the achievement of minimum annual net sales thresholds and additional double-digit royalty payments on net sales.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Galapagos Presents Favorable Phase 1 Data for IBD Target
Galapagos NV discloses GPR84 as a promising novel target for treating inflammatory bowel disease during an oral presentation at United European Gastroenterology Week in Vienna.
Tuesday, October 21, 2014
Galapagos Reports Positive Phase 1 Results for GLPG1205
Company is developing GLPG1205 within its alliance with Janssen Pharmaceutica NV.
Wednesday, December 04, 2013
Galapagos Appoints David Smith as CEO of Service Division
David Smith was CFO of Galapagos for two years.
Wednesday, August 21, 2013
Galapagos Starts Phase Ib Clinical Study in Cancer Patients
Galapagos plans to assess the safety and explore the preliminary efficacy of GLPG0187 in cancer patients.
Tuesday, March 15, 2011
Galapagos Candidate Cachexia Drug, GLPG0492, Shows Good Safety and Profile Suitable for Once-Daily Oral Dosing
Company plans to initiate extended dose and Proof of Concept studies in 2011.
Friday, December 03, 2010
Galapagos Starts Phase II Clinical Trial in Rheumatoid Arthritis Patients
Galapagos NV announced that it has started a Phase II clinical study for the Company’s flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis (RA).
Tuesday, October 19, 2010
Galapagos' Affiliate BioFocus Extends Collaboration with Chiesi
BioFocus to provide medicinal chemistry and biology services, with an additional option for ADME services, for a Chiesi therapeutic program.
Thursday, October 14, 2010
Galapagos Initiates Phase I Study for JAK inhibitor GLPG0634
Company announces the acquisition of full rights to the compound from GSK.
Monday, August 09, 2010
Galapagos and University of Bristol Enter Drug Discovery Collaboration in Chronic Pain
BioFocus will provide hit-to-lead and lead optimization services for a €3.3 million drug discovery program at the University of Bristol.
Friday, July 16, 2010
Galapagos Completes Phase I Clinical Trials for Rheumatoid Arthritis Candidate Drug GLPG0259
Phase II efficacy study in rheumatoid arthritis patients planned to start later this year.
Wednesday, February 24, 2010
Galapagos Delivers Third Candidate Drug in GSK Alliance, Receives €5.7 Million
Galapagos will now start scale-up chemistry and safety evaluation to initiate Phase I clinical trials early 2011.
Tuesday, February 23, 2010
Galapagos Acquires Argenta Discovery's Service Operations
Newly acquired, worth €16.5 million, Argenta unit will operate in parallel to BioFocus.
Friday, February 05, 2010
Galapagos Initiates Nanocort® Phase II Clinical Trial for Multiple Sclerosis
A single administration of Nanocort will be compared to the standard steroid treatment of three methylprednisolone infusions to evaluate Nanocort in treating MS.
Tuesday, November 24, 2009
Galapagos Initiates Second Phase I Clinical Trial for GLPG0259
The new trial is based on the positive outcome of the first-in-human trial conducted earlier in 2009.
Thursday, September 10, 2009
Galapagos Successfully Completes First Phase I Study for GLPG0259
Clinical results demonstrate safety in man Pharmacokinetic profile supports once-daily oral dosing.
Thursday, August 06, 2009
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos